Latest Anthracyclines Stories
BIRMINGHAM, Ala., Jan.
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.
Company does not expect estimated timelines to materially change LOS ANGELES, Jan.
Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability LOS ANGELES, Jan.
QUÉBEC CITY, Dec. 29, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
Company Continues to Expect Clinical Trial Timelines to Remain Materially Unchanged and Expeditiously Resolved LOS ANGELES, Dec.
Company expects Induction Response Rate data in Second Quarter of 2015 EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc.
All amounts are in U.S. dollars QUÉBEC CITY, Dec. 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
EWING, N.J., Nov. 24, 2014 /PRNewswire/ -- Celator Pharmaceuticals, Inc.
All Currently Enrolled Patients Can Continue Receiving Aldoxorubicin Therapy or Comparator Drugs; One Inclusion/Exclusion Criteria to be Amended for New Trial Patients to Add Additional Safety Measure
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.